Recurrent gout with major cardiovascular disease — SCE Rheumatology MCQ

Correct answer: D — Initiate allopurinol with monthly serum-urate-guided dose escalation and offer colchicine prophylaxis during titration

This patient should be offered urate-lowering therapy because he has multiple troublesome flares. Treatment can now be initiated because his last flare settled 6 weeks ago. NICE recommends a treat-to-target strategy, starting ULT at a low dose and using monthly serum urate measurements to guide escalation until the target is reached. His previous myocardial infarction constitutes major cardiovascular disease, for which allopurinol is the recommended first-line agent. Colchicine should be offered to prevent mobilisation flares while the serum urate target is being reached. Febuxostat is a reasonable first-line alternative for many patients, but allopurinol is preferred in those with major cardiovascular disease; current MHRA advice also recommends caution when initiating febuxostat in this population. Deferring ULT is inappropriate after three troublesome flares. Starting allopurinol directly at 300 mg and monitoring only annually omits low-dose initiation and monthly treat-to-target titration; annual monitoring is considered after the target has been achieved on stable treatment. Continuous colchicine can suppress flares but does not lower serum urate or eliminate the underlying monosodium urate crystal burden.

Reference: NICE NG219: Gout—diagnosis and management, recommendations 1.5.1 and 1.5.4-1.5.15 (9 June 2022; current page checked 19 August 2026) — https://www.nice.org.uk/guidance/ng219/chapter/Recommendations MHRA Drug Safety Update: Febuxostat—updated advice for the treatment of patients with a history of major cardiovascular disease (25 May 2023) — https://www.gov.uk/drug-safety-update/febuxostat-updated-advice-for-the-treatment-of-patients-with-a-history-of-major-cardiovascular-disease